Target Validation in Drug Discovery

Target Validation in Drug Discovery, 1st Edition

Target Validation in Drug Discovery, 1st Edition,Brian Metcalf,Susan Dillon,ISBN9780123693938

Metcalf   &   Dillon   

Academic Press




260 X 184

Print Book + eBook

USD 135.00
USD 225.00

Buy both together and save 40%

Print Book


In Stock

Estimated Delivery Time
USD 115.00

eBook Overview

VST (VitalSource Bookshelf) format

DRM-free included formats : PDF

USD 110.00
Add to Cart


This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.


Professionals in biotechnology and pharmaceutical drug discovery and clinical development. Can also include students and academics in the related areas of study.

Brian Metcalf

Affiliations and Expertise

Chief Drug Discovery Officer, Incyte Corporation, Moraga, CA, U.S.A.

Susan Dillon

Affiliations and Expertise

Senior Vice President, Discovery Research Centocor, Johnson & Johnson, Malvern, PA, U.S.A.

Target Validation in Drug Discovery, 1st Edition

Section Contents
I. Pharmaceutical Biotechnology for Target Validation
II. Target Validation for Biopharmaceutical Drug Discovery
III. Validating Targets of Small Molecule Approaches

Cyber Week Pre-Sale | Use Code CYBOOK15

Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy

Contact Us